TipRanksStock Market NewsAZN NewsAstraZeneca (AZN) Receives a Buy from Leerink Partners

AstraZeneca (AZN) Receives a Buy from Leerink Partners

Leerink Partners analyst Andrew Berens maintained a Buy rating on AstraZeneca (AZNResearch Report) yesterday. The company’s shares closed last Friday at $66.40.

According to TipRanks.com, Berens is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.9% and a 37.7% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.

AstraZeneca has an analyst consensus of Moderate Buy.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $71.70 and a one-year low of $50.66. Currently, AstraZeneca has an average volume of 8.03M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1992, UK-based AstraZeneca Plc is a leading global pharmaceutical company, which is engaged in delivering life-changing medicines. The company produces and commercializes medicines for cancer, gastrointestinal, cardiovascular, neuroscience, oncology, respiratory and inflammation and other infectious diseases.

Read More on AZN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More